Testing for brain and spinal cord cancers is a climb no one should face alone.
Next-gen sequencing is being developed to detect aneuploidy, mutations, and methylation with our cerebrospinal fluid testing platform.
High-performance assay to detect brain and spinal cord cancers
Accurate cancer detection is critical for improving treatment decisions, but cytology is inadequate and biopsies are invasive and risky. Our high-performance cerebrospinal fluid assay is designed to offer an innovative alternative.
Your partner in a higher standard of care
Improving diagnosis for brain and spinal cord cancers can give people the best chance for a cure without the need for invasive biopsies. We see our technological advances in cerebrospinal fluid assays as offering clinicians alternative diagnostic tools for use in treatment decisions.
High-performance assay to detect brain and spinal cord cancers
Accurate cancer detection is critical for improving treatment decisions, but cytology is inadequate and biopsies are invasive and risky. Our high-performance cerebrospinal fluid assay is designed to offer an innovative alternative.
Your partner in a higher standard of care
Improving diagnosis for brain and spinal cord cancers can give people the best chance for a cure without the need for invasive biopsies. We see our technological advances in cerebrospinal fluid assays as offering clinicians alternative diagnostic tools for use in treatment decisions.